更新于：2024-11-01

type 2 diabetes mellitus with peripheral neuropathy

2型糖尿病伴有周围神经病

更新于：2024-11-01

基本信息

别名

diabetic peripheral neuropathy type 2、type 2 diabetes mellitus with peripheral neuropathy、type 2 diabetes mellitus with peripheral neuropathy (diagnosis)

简介-

关联

项与 2型糖尿病伴有周围神经病相关的药物

Adezunap

靶点-

作用机制-

在研机构

Apurano Pharmaceuticals GmbH

原研机构

Cannaxan GmbH

在研适应症

创伤性脑损伤 [+11]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

VUM-02

靶点-

作用机制

干细胞替代物

在研机构

武汉光谷中源药业有限公司 [+1]

原研机构

武汉光谷中源药业有限公司

在研适应症

急性移植物抗宿主病 [+6]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

Xiaoke Tongluo Capsule

消渴通络胶囊

靶点-

作用机制-

在研机构-

原研机构-

在研适应症-

非在研适应症

2型糖尿病伴有周围神经病

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与 2型糖尿病伴有周围神经病相关的临床试验

IRCT20200107046035N13 / RecruitingN/AIIT

The Effect of Aquatic Exercise Program on Range of Motion, Foot Pressure Distribution, Proprioception, Gait Characteristics, and Quality of Life among Individuals with Diabetic Neuropathy

开始日期2024-10-06

申办/合作机构

Hakim Sabzevari University

IRCT20200107046035N12 / RecruitingN/AIIT

Comparison of the Effect of a Training Course in Deep and Shallow Water on Flat Foot, Balance, Lower Limb Strength, Fatigue and Performance in Neuropathic Diabetics

开始日期2024-10-06

申办/合作机构

Hakim Sabzevari University

IRCT20240611062084N1 / RecruitingN/AIIT

Comparison of the effect of strengthening exercises and Intermittent Pneumatic Compression (IPC) application on nitric oxide serum level and quality of life in people with type 2 diabetes neuropathy

开始日期2024-08-05

申办/合作机构

Tarbiat Modares University

100 项与 2型糖尿病伴有周围神经病相关的临床结果

登录后查看更多信息

100 项与 2型糖尿病伴有周围神经病相关的转化医学

登录后查看更多信息

0 项与 2型糖尿病伴有周围神经病相关的专利（医药）

登录后查看更多信息

项与 2型糖尿病伴有周围神经病相关的文献（医药）

2024-03-01·Journal of Diabetes

Diagnostic biomarker for type 2 diabetic peripheral neuropathy via comprehensive bioinformatics analysis

Article

作者: Chen, Niyao ; Zhang, Haibin ; Ma, Jiangxin ; Huang, Huibin ; Liu, Qingquan ; Wu, Xiaohong ; Chen, Xiaoyu ; Yu, Liying

AbstractBackgroundDiabetic peripheral neuropathy (DPN) is a common complication of Type 2 diabetes mellitus (T2DM), which frequently results in disabling neuropathic pain and lower‐limb amputation. The identification of noninvasive biomarkers for DPN may help early detection and individualized treatment of DPN.MethodsIn this study, we identified differentially expressed genes (DEGs) between DPN and the control based on blood‐source (GSE95849) and tissue‐source gene expression profiles (GSE143979) from the Gene Expression Omnibus (GEO) database using limma, edgeR, and DESeq2 approaches. KEGGG and GO functional enrichments were performed. Hub genes and their correlation with infiltrating immune cells were analyzed. Real‐time quantitative polymerase chain reaction (RT‐qPCR) was used to quantify hub gene expression.ResultsIn total, 144 DEGs between DPN and the control were identified. Functional enrichment revealed that the DEGs were mainly enriched in immune‐related pathways like the Fc epsilon receptor Ig signaling pathway. By protein–protein interaction (PPI) network analysis, FCER1G, SYK, ITGA4, F13A1, MS4A2, and PTK2B were screened as hub genes with higher expression in DPN patients, among which half were immune genes (FCER1G, PTK2B, and SYK). RT‐qPCR demonstrated that mRNA expression of FCER1G, PTK2B, and SYK was significantly increased in patients with DPN compared with both diabetic nonperipheral neuropathy (DNN) and normal subjects. The area under the receiver operating characteristic (ROC) curve of FCER1G, PTK2B, and SYK was 0.84, 0.81, and 0.73, respectively, suggesting their great advantages as diagnostic biomarkers to predict the progression of neuropathy in T2DM. Further analysis indicated that the expression of FCER1G, PTK2B, and SYK was negatively correlated with the cell proportion of significantly altered resting natural killer cells, T follicular helper cells, and activated mast cells, but positively correlated with monocytes.ConclusionsOur findings demonstrated FCER1G, PTK2B, and SYK are potential diagnostic biomarkers and therapeutic targets for DPN, which provides new insight into DPN pathogenesis and therapies.

image

2024-01-01·Journal of Diabetes Investigation

Sympathetic skin response for early detection of type 2 diabetic peripheral neuropathy and nephropathy

Article

作者: Gao, Qingchun ; Liu, Hongying ; Tan, Sheng ; Ma, Zhenyu ; Yang, Weihong

ABSTRACTBackgroundDiabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) are common complications of type 2 diabetes mellitus (T2DM). Although nerve conduction studies (NCS) and sympathetic skin response (SSR) can detect DPN, the more sensitive method for early diagnosis remains unclear. Furthermore, whether DPN can be used as a predictor for diabetic nephropathy needs clarification.MethodsWe evaluated nerve conduction studies, sympathetic skin response, and the diabetic nephropathy indicator microalbuminuria (MAU) in 192 patients with type 2 diabetes mellitus and 50 healthy controls.ResultsPatients with type 2 diabetes mellitus showed a lower sensory nerve conduction velocity (SCV), sensory active nerve potential (SNAP), motor nerve conduction velocity (MCV), and compound motor action potential (CMAP) than the controls on NCS. Abnormal rates for nerve conduction studies and sympathetic skin response were 75.0% and 83.3%, respectively, in patients with type 2 diabetes mellitus. Interestingly, 54.2% of patients with normal nerve conduction studies had an abnormal sympathetic skin response. Moreover, we found a positive correlation between sympathetic skin response and microalbuminuria for the first time. The abnormal rate of microalbuminuria was 53.8%, lower than that of abnormal nerve conduction studies or sympathetic skin response patients.ConclusionSympathetic skin response is a more sensitive method than nerve conduction studies for the early diagnosis of diabetic peripheral neuropathy. Abnormal sympathetic skin response might serve as an indicator for early diabetic nephropathy. Additionally, diabetic peripheral neuropathy may occur earlier than diabetic nephropathy in the development of type 2 diabetes mellitus.

2023-10-04·Cureus

Association of Sensory Nerve Action Potential Amplitude and Velocity With Type 2 Diabetic Peripheral Neuropathy

Article

作者: Tauheed, Nazia ; Siddiqui, Anwar H ; Ahmad, Jamal ; Ashraf, Hamid

BACKGROUNDThere is ongoing controversy regarding the predominant type of nerve injury in diabetic peripheral neuropathy, whether it is demyelination or axonal degeneration.OBJECTIVEThis study aimed to investigate the association between nerve conduction study parameters, specifically nerve conduction velocity and the amplitude of the action potential, with diabetic peripheral neuropathy and determine their potential as early indicators of the condition.METHODSA cross-sectional study was conducted involving diagnosed type 2 diabetes mellitus patients, who were divided into two groups: Group I (n = 111) with symptomatic diabetic peripheral neuropathy and Group II (n = 109) without clinically detectable peripheral neuropathy. Age and sex-matched healthy controls (n = 100) were also included. Nerve conduction velocity measurements were performed on both upper and lower limbs, with motor nerve conduction study focusing on the dominant side using the median and posterior tibial nerves and sensory nerve conduction study using the median and sural nerves.RESULTSThe nerve conduction studies revealed significantly lower sensory nerve action potential amplitudes and compound muscle action potential amplitudes in the median, posterior tibial, and sural nerves of the diabetic groups compared to the control subjects. Furthermore, these changes were more prominent in patients with peripheral neuropathy. Among the 220 diabetic patients analyzed, 135 (61.36%) exhibited nerve conduction abnormalities. The highest rate of abnormality was observed in the sural nerve, followed by the posterior tibial and median nerves. The most common abnormality detected in diabetic patients was a decrease in sensory nerve action potential, followed by a decrease in sensory nerve conduction velocity.CONCLUSIONThe study findings suggest an association between reduced sensory nerve action potential amplitude and diabetic peripheral neuropathy. These results highlight the potential of sensory nerve action potential and velocity as a sensitive indicator of peripheral neuropathy in diabetic patients.